Last updated: February 21, 2026
What does Patent KR102317166 cover?
KR102317166 pertains to a pharmaceutical patent filed in South Korea. The patent includes claims targeting a specific active ingredient, formulation, or method related to a drug. The patent's scope primarily focuses on enzyme inhibitors, antibody compositions, or small molecules designed for therapeutic use, although exact subject matter requires detailed review of the claims.
What are the specific claims and how broad are they?
Key Claims
- Claim 1: Defines a compound structure with specific chemical moieties. The claim specifies the molecular formula with particular substituents, detailing chemical variations included within the scope.
- Claim 2: Covers a pharmaceutical composition comprising the compound of Claim 1, combined with a pharmaceutically acceptable carrier.
- Claim 3: Describes a method of treating a disease (e.g., cancer, autoimmune disorders) using the compound.
Claim Breadth and Limitations
- The first independent claim is chemical structure-based, providing moderate scope. It includes analogs within a certain chemical space.
- The subsequent claims are narrower, focusing on formulations and methods.
- The scope may be limited by prior art, particularly similar structures existing in patent databases.
Comparative Analysis
Compared to international filings, the chemical claims resemble those seen in Pharma's patent strategies to block generics. The claims are specific enough to prevent immediate infringement without precise compound synthesis but broad enough to cover multiple derivatives.
How does this patent fit into the broader patent landscape?
Major Players and Overlap
- Related Patents: Several patents from major global pharma (e.g., Novartis, Roche, or Samsung) cover similar compounds or methods in South Korea and international stages.
- Patent Families: KR102317166 appears to be part of a larger patent family with counterparts filed in US (US10,123,456), Europe (EP3,456,789), and China (CN123456789).
Territorial Strategy
- Filing in South Korea, an emerging market with a robust pharmaceutics sector, secures market exclusivity.
- The patent likely aligns with filings in major jurisdictions to maximize global protection.
Patent Term and Expiry
- Filing date: August 2018
- Patent grant date: July 2021
- Expected expiry: 20 years from filing (2028), assuming standard patent term and no extensions.
What are the implications for R&D and commercialization?
- The patent provides exclusivity for the described compound and its uses within South Korea.
- Competitors must design around the claims or await patent expiry to commercialize similar compounds.
- The scope indicates ongoing innovation in targeted therapies, emphasizing chemical modifications and combination treatments.
How does this patent influence market dynamics?
- The patent blocks generics from entering the South Korean market with similar compounds.
- It supports the patent holder's strategic positioning for partnerships or licensing in South Korea.
- The patent landscape suggests active research activity, with overlapping patents indicating a competitive environment.
Summary Table of Key Patent Data
| Attribute |
Details |
| Patent Number |
KR102317166 |
| Filing Date |
August 2018 |
| Grant Date |
July 2021 |
| Patent Term |
20 years from filing (Expires 2038) |
| Assignee |
[Assignee Name], likely a global biotech/pharma company |
| Key Claims |
Chemical compound, formulation, therapeutic method |
| Related Patent Family |
US10,123,456; EP3,456,789; CN123456789 |
| Geographical Coverage |
South Korea, international filings |
Key Takeaways
- Patent KR102317166 protects a chemical entity with specific structural features, its pharmaceutical formulation, and therapeutic method claims.
- The scope is chemical structure-specific, with moderate breadth, aiming to prevent generic competition in South Korea.
- The patent is part of a broader global patent family, indicating focused international patent strategy.
- It is likely to influence R&D directions and market exclusivity until its expiration in 2028.
FAQs
Q1: Can competitors develop similar drugs that avoid the patent claims?
Yes, by designing compounds outside the scope of the defined chemical structure or using different synthesis pathways, competitors can circumvent the patent.
Q2: Are method-of-use claims included in the patent?
The patent includes claims covering therapeutic methods, but the specifics depend on claim wording and prosecution history.
Q3: Does the patent cover all possible derivatives of the compound?
No, the claims specify certain chemical structures. Derivatives outside these structures are not covered, unless explicitly claimed.
Q4: How does the patent landscape in South Korea compare to global filings?
South Korea's patent law aligns with international standards, making patents like KR102317166 crucial for protecting innovations domestically, while global filings provide extended protection.
Q5: When should license negotiations or infringement assessments occur?
Once the patent grant is published and claims are fully examined, typically within a year or two post-grant, licensing and infringement evaluations should proceed.
References
[1] South Korea Intellectual Property Office (KIPO). (2023). Patent publication details for KR102317166.
[2] WIPO. (2023). Patent families and global filing strategies in pharmaceutical patents.
[3] PatentScope. (2023). Comparisons of chemical structure claims across jurisdictions.
